Home
Contact
✕
Diane Dragaud
Home
Diane Dragaud
Filter by
Categories
Tags
Authors
Show all
All
Editorials
New Trials
Ongoing Trials
Trial Results
All
Acute lymphoblastic leukemia
Adolescents and young adults
Advocacy
Anal cancer
Antioxidants
Bladder cancer
Blood cancers
Breast cancer
Cancer care delivery
Caregiving
Chemotherapy
Chronic lymphocytic leukemia
Communication
COVID-19
De-escalation
Esophagus cancer
GI cancer
Green tea
Head and neck cancer
Health equity
HER2+ breast cancer
Hormone therapy
Immune system therapy
Immunotherapy
In memory
Kidney cancer
Language
Late Effects
Leukemia
Liver cancer
Lung cancer
Lymphoma
Mammography
Mantle cell lymphoma
Melanoma
Mesothelioma
Minimal residual disease
MRI
Multiple myeloma
Myeloma
NCI-MATCH
Neuropathy
Nose and sinus cancer
Older adults
Pancreatic cancer
Pancreatic cysts
Patient-reported outcomes
Personalized medicine
Personalized screening
Personalized treatment
Precision medicine
Prevention
Prostate cancer
Renal cell carcinoma
Screening
Side effects
Squamous cell carcinoma
Surveillance
Survivorship
Symptom management
Targeted therapy
Throat cancer
Triple-negative breast cancer
Tumor test
All
Diane Dragaud
ecogacrinnews2
Katie Heller
January 5, 2023
January 5, 2023
Categories
Trial Results
Trial Results: The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy
The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
January 5, 2023
January 5, 2023
Categories
Trial Results
Trial Results: A recent ECOG-ACRIN study finds excellent results for patients with acute lymphoblastic leukemia (ALL)
Adding immunotherapy to standard chemotherapy keeps most patients in remission and improves their survival
September 26, 2022
September 26, 2022
Categories
Trial Results
Trial Results: ECOG-ACRIN research round-up – Fall 2022
Summaries of recently reported ECOG-ACRIN research results
June 28, 2022
June 28, 2022
Categories
Ongoing Trials
Ongoing Trial: As the TMIST breast cancer screening trial passes the halfway mark, leaders continue efforts to recruit women from diverse backgrounds
Reaching more women in local communities, especially women of color, will ensure that the trial results apply to all women—and move health equity forward
1
2
3
Next page